<scp>TRE</scp> atment of <scp>AT</scp> opic eczema ( <scp>TREAT</scp> ) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registriesF.M. Vermeulen, Dmitri Wall, Stephan Weidinger et al.|British Journal of Dermatology|2019Cited by 38
Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case seriesAngela L. Bosma, Phyllis I. Spuls, Louise A. A. Gerbens et al.|Clinical and Experimental Dermatology|2021Cited by 29
Real‐world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the <scp>TREAT NL</scp> (<scp>TREatment</scp> of <scp>ATopic</scp> eczema, the Netherlands) registryAnnelie H. Musters, Phyllis I. Spuls, Florine L van Lookeren et al.|Journal of the European Academy of Dermatology and Venereology|2023Cited by 14
Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the <scp>TREatment</scp> of <scp>ATopic</scp> eczema ( <scp>TREAT</scp> ) registry taskforceAnnelie H. Musters, Louise A. A. Gerbens, M.A. Middelkamp‐Hup et al.|Journal of the European Academy of Dermatology and Venereology|2025Cited by 6
特应性湿疹的治疗 (TREAT) 登记工作组:比较 Dupilumab 与其他全身药物治疗中度至重度湿疹安全性的方法Angela L. Bosma, Carsten Flohr, Phyllis I. Spuls et al.|British Journal of Dermatology|2020Cited by 0